Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Bridget A Robinson, Philipp Sergeev, Yoko Kosaka, Thomas Jacob, Andy Kaempf, Evan F. Lind, Cristina Tognon, Luis A. Carvajal, Jorge F. DiMartino, Caroline A. Heckman, Tania Q Vu

Blood (2023) 142 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2023-186506

Published: 2023

Journal Articles

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

Akanksha Pandey, Luis A. Carvajal, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Tressa Hood, Linlin Guo, Tamara D Hopkins, Nikolaus Obholzer, Michael R. McKeown, Jorge F. DiMartino, Charles Y. Lin

Blood (2023) 142 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2023-174114

Published: 2023

Journal Articles

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Monteserrat Arnan, Anand Ashwin Patel, Jordi Esteve, Lawrence Morris, Gary J. Schiller, Ronan T. Swords, Juan M. Alonso-Dominguez, Laura C. Michaelis, Naval Daver, Luis A. Carvajal, Gordon Bray, Elizabeth Olek, Richard E. Cutler, Jorge F. DiMartino, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2023-178804

Published: 2023

Journal Articles

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

Luis A. Carvajal, Michael R. McKeown, Tressa Hood, Linlin Guo, Charles Y. Lin, Jorge F. DiMartino

Blood (2023) 142 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2023-186605

Published: 2023

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

Journal Articles

A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma

Drew W Rasco, MD, Anita K Gandhi, PhD, Angela James, PhD, Shaoyi Li, PhD, Edward O'Mara, MD, Rajesh Chopra, M.D., Ph.D., Jorge F. DiMartino, MD, PhD, Kent Shih, MD

Blood (2013) 122 (21): 2905.

https://doi.org/10.1182/blood.V122.21.2905.2905

Published: 2013

Journal Articles

Environmental Factors Determine Lineage Fate in a Human Model of MLL-AF9 Leukemia.

Junping Wei, MD, PhD, Wunderlich Mark, M.S., Catherine Fox, B.S., Jorge F. DiMartino, M.D., Ph.D, James C. Mulloy, Ph.D

Blood (2007) 110 (11): 3374.

https://doi.org/10.1182/blood.V110.11.3374.3374

Published: 2007

Journal Articles

Leukemic Transformation of Primary Human CD34+ Progenitor Cells by MLL-AF9 Recapitulates the Phenotype and Gene Expression Profile of MLL Rearranged AML.

James C. Mulloy, PhD, Junping Wei, MD PhD, Catherine Rettig, Mark Wunderlich, Sara Alvarez, PhD, Juan Cigudosa, PhD, Michael Jansen, MD, Jorge F. DiMartino, MD PhD

Blood (2006) 108 (11): 2210.

https://doi.org/10.1182/blood.V108.11.2210.2210

Published: 2006

Journal Articles

Retroviral Mediated Transfer of MLL Fusion Genes into Human CD34+ Cord Blood Cells Supports the Establishment of Long-Term Myeloid Cultures with Growth Rates, Immunophenotypic and Transcriptional Features Distinct from Those of AML1-ETO Transduced Cultures.

Jorge F. DiMartino, MD, PhD, Catherine Rettig, BS, Mark Wunderlich, BS, James C. Mulloy, PhD

Blood (2005) 106 (11): 1610.

https://doi.org/10.1182/blood.V106.11.1610.1610

Published: 2005

Journal Articles

Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.

Jorge F. DiMartino, M.D., Ph.D., Norman J. Lacayo, M.D., Marie Varadi, M.S., Yaddanapudi Ravindranath, M.D., Ron Yu, Branimir Sikic, M.D., Susana C. Raimondi, M.D., Gary V. Dahl, M.D.

Blood (2004) 104 (11): 1106.

https://doi.org/10.1182/blood.V104.11.1106.1106

Published: 2004

Journal Articles

The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10

Jorge F. DiMartino, Paul M. Ayton, Everett H. Chen, Clarissa C. Naftzger, Bryan D. Young, Michael L. Cleary

Blood (2002) 99 (10): 3780–3785.

https://doi.org/10.1182/blood.V99.10.3780

Published: 2002

Journal Articles

The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver

Jorge F. DiMartino, Licia Selleri, David Traver, Meri T. Firpo, Joon Rhee, Roger Warnke, Stephen O'Gorman, Irving L. Weissman, Michael L. Cleary

Blood (2001) 98 (3): 618–626.

https://doi.org/10.1182/blood.V98.3.618

Published: 2001

Journal Articles

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL

Jorge F. DiMartino, Trissa Miller, Paul M. Ayton, Theresa Landewe, Jay L. Hess, Michael L. Cleary, Ali Shilatifard

Blood (2000) 96 (12): 3887–3893.

https://doi.org/10.1182/blood.V96.12.3887

Published: 2000

NARROW

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma

Environmental Factors Determine Lineage Fate in a Human Model of MLL-AF9 Leukemia.

Leukemic Transformation of Primary Human CD34+ Progenitor Cells by MLL-AF9 Recapitulates the Phenotype and Gene Expression Profile of MLL Rearranged AML.

Retroviral Mediated Transfer of MLL Fusion Genes into Human CD34+ Cord Blood Cells Supports the Establishment of Long-Term Myeloid Cultures with Growth Rates, Immunophenotypic and Transcriptional Features Distinct from Those of AML1-ETO Transduced Cultures.

Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.

The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10

The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only